E J Favaloro

Summary

Affiliation: New South Wales
Country: Australia

Publications

  1. ncbi Laboratory diagnosis of von Willebrand disorder. Current practice in the southern hemisphere
    Emmanuel J Favaloro
    Department of Haematology, RCPA Quality Assurance Program, Institute of Clinical Pathology and Medical Research, Westmead Hospital, Westmead, Australia
    Am J Clin Pathol 119:882-93. 2003
  2. ncbi Identification of factor inhibitors by diagnostic haemostasis laboratories: a large multi-centre evaluation
    Emmanuel J Favaloro
    Department of Haematology and RCPA Quality Assurance Program QAP, Institute of Clinical Pathology and Medical Research ICPMR, Westmead Hospital, Westmead, New South Wales, Australia
    Thromb Haemost 96:73-8. 2006
  3. ncbi Standardization, regulation, quality assurance and emerging technologies in hemostasis: issues, controversies, benefits, and limitations
    Emmanuel J Favaloro
    Department of Haematology, Institute of Clinical Pathology and Medical Research, Westmead Hospital, New South Wales, Australia
    Semin Thromb Hemost 33:290-7. 2007
  4. ncbi Time to think outside the box? Prothrombin time, international normalised ratio, international sensitivity index, mean normal prothrombin time and measurement of uncertainty: a novel approach to standardisation
    Emmanuel J Favaloro
    Department of Haematology, Institute of Clinical Pathology and Medical Research, Westmead Hospital, Westmead, New South Wales, Australia
    Pathology 40:277-87. 2008
  5. ncbi Biological therapies for von Willebrand disease
    Emmanuel J Favaloro
    Institute of Clinical Pathology and Medical Research ICPMR, Westmead Hospital, Department of Haematology, Westmead, NSW, 2145, Australia 612 9845 6618 612 9689 2331
    Expert Opin Biol Ther 12:551-64. 2012
  6. ncbi Diagnosis and management of von Willebrand disease in Australia
    Emmanuel J Favaloro
    Department of Haematology, Institute of Clinical Pathology and Medical Research, Westmead Hospital, NSW, Australia
    Semin Thromb Hemost 37:542-54. 2011
  7. ncbi Von Willebrand disease: local diagnosis and management of a globally distributed bleeding disorder
    Emmanuel J Favaloro
    Department of Haematology, Institute of Clinical Pathology and Medical Research, Westmead Hospital, NSW, Australia
    Semin Thromb Hemost 37:440-55. 2011
  8. ncbi The diagnostic dilemma: dual presentations of clinical mucosal bleeding and venous thrombosis associated with the presence of thrombophilia markers and mild reduction in von Willebrand factor
    Emmanuel J Favaloro
    Diagnostic Hemostasis and Molecular Diagnostics Laboratories, Department of Hematology and RCPA Hematology QAP, Institute of Clinical Pathology and Medical Research, Westmead Hospital, Westmead NSW, Australia
    Lab Hematol 13:128-34. 2007
  9. ncbi Internal quality control and external quality assurance of platelet function tests
    Emmanuel J Favaloro
    Department of Haematology, Institute of Clinical Pathology and Medical Research, Westmead Hospital, Westmead, NSW 2145, Australia
    Semin Thromb Hemost 35:139-49. 2009
  10. ncbi Potential supplementary utility of combined PFA-100 and functional von Willebrand factor testing for the laboratory assessment of desmopressin and factor concentrate therapy in von Willebrand disease
    Emmanuel J Favaloro
    Department of Haematology, Institute of Clinical Pathology and Medical Research ICPMR, Westmead Hospital, New South Wales, Australia
    Blood Coagul Fibrinolysis 20:475-83. 2009

Detail Information

Publications113 found, 100 shown here

  1. ncbi Laboratory diagnosis of von Willebrand disorder. Current practice in the southern hemisphere
    Emmanuel J Favaloro
    Department of Haematology, RCPA Quality Assurance Program, Institute of Clinical Pathology and Medical Research, Westmead Hospital, Westmead, Australia
    Am J Clin Pathol 119:882-93. 2003
    ..Laboratories generally are proficient in tests for vWD, and transport of samples at 4 degrees C before processing may lead to false identification of vWD, suggesting that NCCLS guidelines should be reviewed...
  2. ncbi Identification of factor inhibitors by diagnostic haemostasis laboratories: a large multi-centre evaluation
    Emmanuel J Favaloro
    Department of Haematology and RCPA Quality Assurance Program QAP, Institute of Clinical Pathology and Medical Research ICPMR, Westmead Hospital, Westmead, New South Wales, Australia
    Thromb Haemost 96:73-8. 2006
    ..In addition, there is a significant false positive error rate where some laboratories will identify the presence of specific factor inhibitors where no such inhibitor exists (i.e. false positives)...
  3. ncbi Standardization, regulation, quality assurance and emerging technologies in hemostasis: issues, controversies, benefits, and limitations
    Emmanuel J Favaloro
    Department of Haematology, Institute of Clinical Pathology and Medical Research, Westmead Hospital, New South Wales, Australia
    Semin Thromb Hemost 33:290-7. 2007
    ..Although this review notes many of the benefits to the process, it focuses primarily on those negative factors that are often less obvious but still require attention and process review...
  4. ncbi Time to think outside the box? Prothrombin time, international normalised ratio, international sensitivity index, mean normal prothrombin time and measurement of uncertainty: a novel approach to standardisation
    Emmanuel J Favaloro
    Department of Haematology, Institute of Clinical Pathology and Medical Research, Westmead Hospital, Westmead, New South Wales, Australia
    Pathology 40:277-87. 2008
    ..Current recommendations suggest the use of commercial reference-plasma calibration sets, but there is limited information on the performance of these in the field...
  5. ncbi Biological therapies for von Willebrand disease
    Emmanuel J Favaloro
    Institute of Clinical Pathology and Medical Research ICPMR, Westmead Hospital, Department of Haematology, Westmead, NSW, 2145, Australia 612 9845 6618 612 9689 2331
    Expert Opin Biol Ther 12:551-64. 2012
    ..Recombinant VWF has been developed and is undergoing clinical trials, and this promising therapy may change the VWD management landscape in the near future...
  6. ncbi Diagnosis and management of von Willebrand disease in Australia
    Emmanuel J Favaloro
    Department of Haematology, Institute of Clinical Pathology and Medical Research, Westmead Hospital, NSW, Australia
    Semin Thromb Hemost 37:542-54. 2011
    ..9%) because available data are limited. Type 2A and 2M VWD represent the most common qualitative defects, representing 22.8% and 22.2% of defined type 2 VWD cases. Type 2B and 2N reflect 8.3% and 12.9%, respectively, of type 2 VWD cases...
  7. ncbi Von Willebrand disease: local diagnosis and management of a globally distributed bleeding disorder
    Emmanuel J Favaloro
    Department of Haematology, Institute of Clinical Pathology and Medical Research, Westmead Hospital, NSW, Australia
    Semin Thromb Hemost 37:440-55. 2011
    ..In contrast, the relative high cost and unavailability of factor concentrates in developing countries, and sometimes the unavailability of DDAVP, requires different management strategies to be applied...
  8. ncbi The diagnostic dilemma: dual presentations of clinical mucosal bleeding and venous thrombosis associated with the presence of thrombophilia markers and mild reduction in von Willebrand factor
    Emmanuel J Favaloro
    Diagnostic Hemostasis and Molecular Diagnostics Laboratories, Department of Hematology and RCPA Hematology QAP, Institute of Clinical Pathology and Medical Research, Westmead Hospital, Westmead NSW, Australia
    Lab Hematol 13:128-34. 2007
    ....
  9. ncbi Internal quality control and external quality assurance of platelet function tests
    Emmanuel J Favaloro
    Department of Haematology, Institute of Clinical Pathology and Medical Research, Westmead Hospital, Westmead, NSW 2145, Australia
    Semin Thromb Hemost 35:139-49. 2009
    ..EQA organizations may be best placed to act as facilitators to the process of improving diagnostic testing for platelet function, which supplements the role of expert organizations...
  10. ncbi Potential supplementary utility of combined PFA-100 and functional von Willebrand factor testing for the laboratory assessment of desmopressin and factor concentrate therapy in von Willebrand disease
    Emmanuel J Favaloro
    Department of Haematology, Institute of Clinical Pathology and Medical Research ICPMR, Westmead Hospital, New South Wales, Australia
    Blood Coagul Fibrinolysis 20:475-83. 2009
    ..Future prospective investigations are warranted to validate these relationships and to investigate their therapeutic implications...
  11. ncbi The Journal Impact Factor: don't expect its demise any time soon
    Emmanuel J Favaloro
    Department of Hematology, Institute of Clinical Pathology and Medical Research ICPMR, Westmead Hospital, SWAHS, Westmead, NSW, Australia
    Clin Chem Lab Med 47:1319-24. 2009
    ..Accordingly, despite our love-hate relationship with the IF, don't expect its demise any time soon...
  12. ncbi Identification and prevalence of von Willebrand disease type 2N (Normandy) in Australia
    Emmanuel J Favaloro
    Department of Haematology, Institute of Clinical Pathology and Medical Research, Westmead Hospital, Westmead, New South Wales, Australia
    Blood Coagul Fibrinolysis 20:706-14. 2009
    ....
  13. ncbi Laboratory investigation of thrombophilia: the good, the bad, and the ugly
    Emmanuel J Favaloro
    Department of Haematology, Institute of Clinical Pathology and Medical Research ICPMR, Westmead Hospital, NSW, Australia
    Semin Thromb Hemost 35:695-710. 2009
    ..In short, it is likely that current generalized testing is simply doing more harm than good, and thus that ordering practice requires scrutiny...
  14. ncbi Laboratory reporting of hemostasis assays: the final post-analytical opportunity to reduce errors of clinical diagnosis in hemostasis?
    Emmanuel J Favaloro
    Department of Hematology, Institute of Clinical Pathology and Medical Research ICPMR, Westmead Hospital, SWAHS, Westmead, NSW, Australia
    Clin Chem Lab Med 48:309-21. 2010
    ..Also, clinicians will not be in a position to best diagnose and manage their patient unless they gain an appreciation of these issues...
  15. ncbi Laboratory identification of factor VIII inhibitors in the real world: the experience from Australasia
    E J Favaloro
    Department of Haematology, Institute of Clinical Pathology and Medical Research, Westmead Hospital, NSW, Australia
    Haemophilia 16:662-70. 2010
    ..In conclusion, our study indicates that there is still much need for standardization and improvement in factor inhibitor detection, and we hope that our findings provide a basis for future improvements in this area...
  16. ncbi Current clinical and laboratory practice for the investigation of the antiphospholipid syndrome: findings from the 2008 Australasian antiphospholipid antibody survey
    Emmanuel J Favaloro
    Department of Haematology, Institute of Clinical Pathology and Medical Research ICPMR, Westmead Hospital, New South Wales, Australia
    Pathology 41:666-75. 2009
    ..Depending on their clinical presentation, affected individuals might be seen by a variety of clinical specialties including general physicians and general practionners, with a potentially wide variation in the aPL assays requested...
  17. ncbi Toward a new paradigm for the identification and functional characterization of von Willebrand disease
    Emmanuel J Favaloro
    Department of Haematology, Institute of Clinical Pathology and Medical Research, Westmead Hospital, SWAHS, Westmead, Australia
    Semin Thromb Hemost 35:60-75. 2009
    ..The potential use of supplementary assays such as the PFA-100 and the VWF propeptide assay after DDAVP challenge is also worth noting...
  18. ncbi Clinical utility of the PFA-100
    Emmanuel J Favaloro
    Department of Haematology, Institute of Clinical Pathology and Medical Research, Westmead Hospital, NSW, Australia
    Semin Thromb Hemost 34:709-33. 2008
    ..The potential future applications for this simple instrument are also briefly assessed...
  19. ncbi Measuring the quality of journals and journal articles: the impact factor tells but a portion of the story
    Emmanuel J Favaloro
    Department of Haematology, Institute of Clinical Pathology and Medical Research, Westmead Hospital, Westmead, Australia
    Semin Thromb Hemost 34:7-25. 2008
    ..The evaluation of previously published articles also helps serve to illustrate, by example, some of the limitations to the use of the impact factor as the sole determinant of a journal's "quality."..
  20. ncbi Lower limit of assay sensitivity: an under-recognised and significant problem in von Willebrand disease identification and classification
    Emmanuel J Favaloro
    Department of Haematology, Institute of Clinical Pathology and Medical Research, Westmead Hospital, Westmead, NSW, Australia
    Clin Lab Sci 21:178-83. 2008
    ..However, the laboratory testing process is problematic because of both the heterogeneity of VWD and the limitations in the tests used to identify reduced or abnormal VWF...
  21. ncbi Time to think outside the box? Proposals for a new approach to future pharmacokinetic studies of von Willebrand factor concentrates in people with von Willebrand disease
    Emmanuel J Favaloro
    Department of Haematology, Institute of Clinical Pathology and Medical Research ICPMR, Westmead Hospital, Westmead, Australia
    Semin Thromb Hemost 33:745-58. 2007
    ..We suggest that these test parameters may be useful in future PK studies to better assess and compare the potential utility and clinical efficacy of VWF factor concentrates for use as therapy for VWD...
  22. ncbi Laboratory testing and identification of antiphospholipid antibodies and the antiphospholipid syndrome: a potpourri of problems, a compilation of possible solutions
    Emmanuel J Favaloro
    Department of Haematology, Institute of Clinical Pathology and Medical Research ICPMR, Westmead Hospital, NSW, Australia
    Semin Thromb Hemost 34:389-410. 2008
    ....
  23. ncbi Desmopressin therapy to assist the functional identification and characterisation of von Willebrand disease: differential utility from combining two (VWF:CB and VWF:RCo) von Willebrand factor activity assays?
    Emmanuel J Favaloro
    Department of Haematology, Institute of Clinical Pathology and Medical Research ICPMR, Westmead Hospital, NSW, Australia
    Thromb Res 123:862-8. 2009
    ..7. Future multi-centre prospective investigations are warranted to validate these findings and to investigate their therapeutic implications...
  24. ncbi Standardization of the INR: how good is your laboratory's INR and can it be improved?
    Emmanuel J Favaloro
    Department of Haematology, ICPMR, Westmead Hospital, Westmead, Australia
    Semin Thromb Hemost 34:593-603. 2008
    ..We detail various strategies to ensure that laboratory practices are optimized to provide INRs that accurately reflect a patient's true anticoagulant status and to thus assist their clinical therapeutic management...
  25. ncbi An update on the von Willebrand factor collagen binding assay: 21 years of age and beyond adolescence but not yet a mature adult
    Emmanuel J Favaloro
    Department of Haematology, Institute of Clinical Pathology and Medical Research ICPMR, Westmead Hospital, Westmead, Australia
    Semin Thromb Hemost 33:727-44. 2007
    ....
  26. ncbi Contemporary platelet function testing
    Emmanuel J Favaloro
    Department of Hematology, Institute of Clinical Pathology and Medical Research, Westmead Hospital, Westmead, Australia
    Clin Chem Lab Med 48:579-98. 2010
    ..This review outlines the sequential process of platelet function investigations, and discusses each of the essential components in some detail...
  27. ncbi Distinguishing types 1 and 2M von Willebrand disease
    E J Favaloro
    Department of Haematology, Institute of Clinical Pathology and Medical Research ICPMR, Westmead Hospital, Westmead, NSW, Australia
    Int J Lab Hematol 34:102-5. 2012
    ..We describe a case of 2M VWD 'masquerading' as type 1 and show how the differential diagnosis can be obtained using standard laboratory assays. The case was genetically confirmed as a 3943C>T mutation, leading to R1315C...
  28. ncbi Improving the harmonisation of the International Normalized Ratio (INR): time to think outside the box?
    Emmanuel J Favaloro
    Institute of Clinical Pathology and Medical Research ICPMR, Westmead Hospital, SWAHS, Westmead, Australia
    Clin Chem Lab Med 48:1079-90. 2010
    ....
  29. ncbi A clinical audit of congenital thrombophilia investigation in tertiary practice
    Emmanuel J Favaloro
    Department of Haematology, Institute of Clinical Pathology and Medical Research ICPMR, Westmead Hospital, Westmead, New South Wales 2145, Australia
    Pathology 43:266-72. 2011
    ..However, the effectiveness of such evaluations is largely determined by limiting improper investigations, either in inappropriate patients or at unsuitable timepoints...
  30. ncbi Laboratory testing for the antiphospholipid syndrome: making sense of antiphospholipid antibody assays
    Emmanuel J Favaloro
    Department of Haematology, Institute of Clinical Pathology and Medical Research ICPMR, Westmead Hospital, NSW, Australia
    Clin Chem Lab Med 49:447-61. 2011
    ....
  31. ncbi Rethinking the diagnosis of von Willebrand disease
    Emmanuel J Favaloro
    Department of Haematology, Institute of Clinical Pathology and Medical Research ICPMR, Westmead Hospital, NSW, Australia
    Thromb Res 127:S17-21. 2011
    ..The current review briefly covers this diagnostic process, with a focus on newer approaches, including extended test panels and the use of data from desmopressin challenges as a diagnostic tool...
  32. ncbi Diagnosis and classification of von Willebrand disease: a review of the differential utility of various functional von Willebrand factor assays
    Emmanuel J Favaloro
    Department of Haematology, Institute of Clinical Pathology and Medical Research, Westmead Hospital, Westmead, New South Wales, Australia
    Blood Coagul Fibrinolysis 22:553-64. 2011
    ..This review aims to update knowledge of current VWD diagnostics with a particular emphasis on 'functional' VWF assays...
  33. ncbi Coagulation update: what's new in hemostasis testing?
    Emmanuel J Favaloro
    Department of Haematology, Institute of Clinical Pathology and Medical Research ICPMR, Westmead Hospital, NSW, Australia
    Thromb Res 127:S13-6. 2011
    ....
  34. ncbi Evaluation of commercial von Willebrand factor collagen binding assays to assist the discrimination of types 1 and 2 von Willebrand disease
    Emmanuel J Favaloro
    Department of Haematology, Institute of Clinical Pathology and Medical Research, Westmead Hospital, New South Wales, Australia
    Thromb Haemost 104:1009-21. 2010
    ..Future standardisation and improvements in some commercial VWF:CB assays are needed before the VWF:CB assay can be more fully and globally utilised for discrimination of VWD types in diagnostic laboratories...
  35. ncbi Laboratory testing in disseminated intravascular coagulation
    Emmanuel J Favaloro
    Department of Haematology, Institute of Clinical Pathology and Medical Research ICPMR, Westmead Hospital, NSW, Australia
    Semin Thromb Hemost 36:458-67. 2010
    ..Also, procalcitonin is an inflammatory biomarker that may be useful within the context of septic DIC, and activated factor X clotting time is an emerging test of procoagulant phospholipids that also seems to hold promise in DIC...
  36. ncbi Preanalytical and postanalytical variables: the leading causes of diagnostic error in hemostasis?
    Emmanuel J Favaloro
    Department of Haematology, ICPMR, Westmead Hospital, Westmead, Australia
    Semin Thromb Hemost 34:612-34. 2008
    ..The latter because unless clinicians gain an appreciation of these issues, they will not be in a position to best manage their patients...
  37. ncbi Platelet function testing: auditing local practice and broader implications
    Emmanuel J Favaloro
    Department of Haematology, Institute of Clinical Pathology and Medical Research ICPMR, Westmead Hospital, NSW, Australia
    Clin Lab Sci 23:21-31. 2010
    ..However, standardization of practice is poorly applied, and experts differ on several aspects of its application...
  38. ncbi Laboratory testing of anticoagulants: the present and the future
    Emmanuel J Favaloro
    Department of Haematology, Institute of Clinical Pathology and Medical Research ICPMR, Westmead Hospital, New South Wales, Australia
    Pathology 43:682-92. 2011
    ....
  39. ncbi Laboratory diagnosis of von Willebrand disorder (vWD) and monitoring of DDAVP therapy: efficacy of the PFA-100 and vWF:CBA as combined diagnostic strategies
    E J Favaloro
    Diagnostic Haemostasis Laboratory, Department of Haematology, ICPMR, Westmead Hospital, Australia
    Haemophilia 7:180-9. 2001
    ..Furthermore, the combined utility of the PFA-100 and vWF:CBA as markers of DDAVP responsiveness may prove to be simple, quick but powerful, predictors for its clinical efficacy...
  40. ncbi Investigations from external quality assurance programs reveal a high degree of variation in the laboratory identification of coagulation factor inhibitors
    Emmanuel J Favaloro
    Department of Haematology, NSW, Australia
    Semin Thromb Hemost 35:794-805. 2009
    ..There is still much need for standardization and improvement in factor inhibitor detection, and we hope that this report provides a basis for future improvements in this area...
  41. ncbi Laboratory diagnosis of von Willebrand's disorder: quality and diagnostic improvements driven by peer review in a multilaboratory test process
    E J Favaloro
    Department of Haematology, Institute of Clinical Pathology and Medical Research, Westmead Hospital, NSW, Australia
    Haemophilia 10:232-42. 2004
    ..We conclude that laboratories are generally proficient in tests for VWD, and that diagnostic error rates are reduced when test panels are more comprehensive and include the VWF:CB...
  42. ncbi Evaluation of primary haemostasis in people with neurofibromatosis type 1
    E J Favaloro
    Department of Haematology, Institute of Clinical Pathology and Medical Research ICPMR, Westmead Hospital, Western Sydney Area Health Service, Westmead, NSW, Australia
    Clin Lab Haematol 26:341-5. 2004
    ..However, as clinically perceived bleeding risk did not appear to be correlated with laboratory test results in most cases, blanket screening of NF-1 individuals for evaluation of laboratory haemostasis may not be warranted...
  43. ncbi Potential laboratory misdiagnosis of hemophilia and von Willebrand disorder owing to cold activation of blood samples for testing
    Emmanuel J Favaloro
    Department of Hematology, Institute of Clinical Pathology and Medical Research, Westmead Hospital, Australia
    Am J Clin Pathol 122:686-92. 2004
    ..Storage and transport at ambient temperature seem acceptable and provide results comparable to freshly centrifuged samples...
  44. ncbi Utility of the PFA-100 for assessing bleeding disorders and monitoring therapy: a review of analytical variables, benefits and limitations
    E J Favaloro
    Diagnostic Haemostasis Laboratory, Department of Haematology, ICPMR, Westmead Hospital, NSW, Australia
    Haemophilia 7:170-9. 2001
    ..This review should be of value to both haemostasis scientists and clinical specialists...
  45. ncbi A simple, whole blood method for assessment of platelet function: application to dietary intervention
    M A Allman-Farinelli
    Department of Biochemistry, Westmead Hospital, University of Sydney, New South Wales, Australia
    Thromb Res 90:163-9. 1998
    ..The sensitivity of this assay method to dietary manipulation was investigated by administration of fish oil capsules at a dose known to decrease platelet aggregation...
  46. ncbi A Review of beta2 -glycoprotein-l antibody testing results from a peer-driven multilaboratory quality assurance program
    Emmanuel J Favaloro
    Department of Haematology, Institute of Clinical Pathology and Medical Research, Westmead Hospital, Westmead, NSW, Australia
    Am J Clin Pathol 127:441-8. 2007
    ..Improvement in standardization of these assays is still required to improve interlaboratory and intermethod concordance of results and interpretation between laboratories and the clinical usefulness of IgG-B2GPI testing...
  47. ncbi Collagen binding assay for von Willebrand factor (VWF:CBA): detection of von Willebrands Disease (VWD), and discrimination of VWD subtypes, depends on collagen source
    E J Favaloro
    Department of Haematology, Institute of Clinical Pathology and Medical Research, Westmead Hospital, Western Sydney Area Health Service, NSW, Australia
    Thromb Haemost 83:127-35. 2000
    ..These latter methodologies tended to be less sensitive to VWF-discordance when compared to that detected by the majority of the VWF:CBA procedures...
  48. ncbi Use of a novel platelet function analyzer (PFA-100) with high sensitivity to disturbances in von Willebrand factor to screen for von Willebrand's disease and other disorders
    E J Favaloro
    Diagnostic Hemostasis Laboratory, Department of Haematology, Institute of Clinical Pathology and Medical Research ICPMR, Westmead Hospital, Western Sydney Area Health Service, Westmead, NSW, Australia
    Am J Hematol 62:165-74. 1999
    ....
  49. ncbi von Willebrand disease: laboratory aspects of diagnosis and treatment
    E J Favaloro
    Institute of Clinical Pathology and Medical Research, Westmead, NSW 2145, Australia
    Haemophilia 10:164-8. 2004
    ..We also report on the clinical profile and diagnosis of VWD in a South American cohort of patients and on the in vitro characteristics of some factor concentrates available for treatment of VWD...
  50. ncbi Discrimination of von Willebrands disease (VWD) subtypes: direct comparison of von Willebrand factor:collagen binding assay (VWF:CBA) with monoclonal antibody (MAB) based VWF-capture systems
    E J Favaloro
    Department of Haematology, Institute of Clinical Pathology and Medical Research, Westmead Hospital, NSW, Australia
    Thromb Haemost 84:541-7. 2000
    ..In conclusion, the VWF:CBA assay proved to offer the best diagnostic predictive tool for a Type 2 VWD defect, while MAB-based systems appear to be less effective in this regard...
  51. ncbi Laboratory testing for von Willebrand's disease: an assessment of current diagnostic practice and efficacy by means of a multi-laboratory survey. RCPA Quality Assurance Program (QAP) in Haematology Haemostasis Scientific Advisory Panel
    E J Favaloro
    Department of Haematology, Institute of Clinical Pathology and Medical Research, Westmead Hospital, Western Sydney Area Health Service, NSW, Australia
    Thromb Haemost 82:1276-82. 1999
    ....
  52. ncbi Reassessment of ABO blood group, sex, and age on laboratory parameters used to diagnose von Willebrand disorder: potential influence on the diagnosis vs the potential association with risk of thrombosis
    Emmanuel J Favaloro
    Department of Haematology, Institute of Clinical Pathology and Medical Research, Westmead Hospital, NSW, Australia
    Am J Clin Pathol 124:910-7. 2005
    ..O group individuals may or may not be at greater risk for bleeding (they have lower levels of vWF and FVIII:C) and are more likely to be diagnosed with vWD. It also is possible that O group status may be protective for thrombosis...
  53. ncbi Appropriate laboratory assessment as a critical facet in the proper diagnosis and classification of von Willebrand disorder
    E J Favaloro
    Diagnostic Haemostasis Laboratory, Department of Haematology, Institute of Clinical Pathology and Medical Research, Westmead Hospital, Western Sydney Area Health Service, Westmead, NSW, Australia
    Best Pract Res Clin Haematol 14:299-319. 2001
    ..The selection of an appropriate combination test panel and testing sequence is crucial for the proper diagnosis and classification of congenital von Willebrand disease...
  54. ncbi A duplex issue: (i) time to re-appraise the diagnosis and classification of von Willebrand disorder, and (ii) clarification of the roles of von Willebrand factor collagen binding and ristocetin cofactor activity assays
    E J Favaloro
    Department of Haematology, Institute of Clinical Pathology and Medical Research, Westmead Hospital, NSW, 2145, Australia
    Haemophilia 8:828-31. 2002
  55. ncbi Medical research in New South Wales 1993-1996 assessed by Medline publication capture
    E J Favaloro
    Institute of Clinical Pathology and Medical Research ICPMR, Westmead Hospital, Western Sydney Area Health Service, NSW
    Med J Aust 169:617-22. 1998
    ..To assess medical research publication output in New South Wales (NSW)...
  56. ncbi How useful is the monitoring of (low molecular weight) heparin therapy by anti-Xa assay? A laboratory perspective
    Emmanuel J Favaloro
    Department of Haematology and RCPA Quality Assurance Program QAP, Institute of Clinical Pathology and Medical Research ICPMR, Westmead Hospital, NSW, Australia
    Lab Hematol 11:157-62. 2005
    ....
  57. ncbi Laboratory identification of familial thrombophilia: do the pitfalls exceed the benefits? A reassessment of ABO-blood group, gender, age, and other laboratory parameters on the potential influence on a diagnosis of protein C, protein S, and antithrombin d
    Emmanuel J Favaloro
    Department of Haematology, Institute of Clinical Pathology and Medical Research ICPMR, Westmead Hospital, NSW, Australia
    Lab Hematol 11:174-84. 2005
    ....
  58. ncbi An international survey of current practice in the laboratory assessment of anticoagulant therapy with heparin
    Emmanuel J Favaloro
    Department of Haematology and Royal College of Pathologists of Australasia Quality Assurance Program, Institute of Clinical Pathology and Medical Research, Westmead Hospital, Westmead, New South Wales, Australia
    Pathology 37:234-8. 2005
    ..We conducted a survey of laboratory practice for assessment of heparin anticoagulant therapy by participants of the Royal College of Pathologists of Australasia Quality Assurance Program (RCPA QAP)...
  59. ncbi Cross-laboratory audit of normal reference ranges and assessment of ABO blood group, gender and age on detected levels of plasma coagulation factors
    Emmanuel J Favaloro
    Department of Haematology, Institute of Clinical Pathology and Medical Research ICPMR, Westmead Hospital, NSW, Australia
    Blood Coagul Fibrinolysis 16:597-605. 2005
    ..Finally, we also performed a cross-laboratory audit of peer laboratory practice and similarly show a wide diversity in normal reference ranges used between different laboratories...
  60. ncbi A comparative multi-laboratory assessment of three factor VIII/von Willebrand factor concentrates
    Emmanuel J Favaloro
    Department of Haematology, Institute of Clinical Pathology and Medical Research ICPMR, Westmead Hospital, WSAHS, Westmead, NSW, Australia
    Thromb Haemost 87:466-76. 2002
    ..In conclusion, study findings indicate some differences in the retention of functional/ HMW VWF between factor concentrates, and this is expected to have significant implications in terms of clinical efficacy for therapy in VWD...
  61. ncbi A practical approach to instrument selection, evaluation, basic financial management and implementation in pathology and research
    Ashraf Mina
    Department of Endocrinology, Institute of Clinical Pathology and Medical Research I C P M R, Westmead Hospital, Westmead, New South Wales, Australia ashraf
    Clin Chem Lab Med 46:1223-9. 2008
    ..We propose that such a process as outlined in our report will protect laboratories from making costly and avoidable mistakes in the acquisition of major equipment...
  62. ncbi A multilaboratory peer assessment quality assurance program-based evaluation of anticardiolipin antibody, and beta2-glycoprotein I antibody testing
    Emmanuel J Favaloro
    Haemostasis Laboratories, Department of Haematology, Institute of Clinical Pathology and Medical Research, Westmead Hospital, Westmead, New South Walls, Australia
    Semin Thromb Hemost 31:73-84. 2005
    ....
  63. ncbi Laboratory diagnosis of von Willebrand disorder: use of multiple functional assays reduces diagnostic error rates
    Emmanuel J Favaloro
    Department of Haematology, Institute of Clinical Pathology and Medical Research, Westmead Hospital, Westmead, New South Wales, Australia
    Lab Hematol 11:91-7. 2005
    ..We conclude that laboratories are generally proficient in their testing for VWD and that diagnostic error rates are substantially reduced when test panels are more comprehensive and include the VWF:CB...
  64. ncbi Activated protein C resistance: the influence of ABO-blood group, gender and age
    Emmanuel J Favaloro
    Department of Haematology, Institute of Clinical Pathology and Medical Research ICPMR, WSAHS, Westmead Hospital, NSW 2145, Australia
    Thromb Res 117:665-70. 2006
    ..Such findings should be considered as potential variables when associating specific laboratory based findings of APCR to clinical thrombophilia conditions...
  65. ncbi Learning from peer assessment: the role of the external quality assurance multilaboratory thrombophilia test process
    Emmanuel J Favaloro
    Haemostasis Laboratories, Department of Haematology, Institute of Clinical Pathology and Medical Research ICPMR, Westmead Hospital, Westmead, New South Wales, Australia
    Semin Thromb Hemost 31:85-9. 2005
    ..This report focuses on some recent trends from these programs...
  66. ncbi Multilaboratory testing of thrombophilia: current and past practice in Australasia as assessed through the Royal College of Pathologists of Australasia Quality Assurance Program for Hematology
    Emmanuel J Favaloro
    Haematology Laboratories, Institute of Clinical Pathology and Medical Research ICPMR, Westmead Hospital, New South Wales, Australia
    Semin Thromb Hemost 31:49-58. 2005
    ..e., false-normal interpretations for deficient plasma or false-abnormal interpretations for normal plasma). The CVs for these assays ranged from 5 to 40%, with highest CVs typically obtained with PS assays...
  67. ncbi Diagnostic issues in thrombophilia: a laboratory scientist's view
    Emmanuel J Favaloro
    Department of Haematology, Institute of Clinical Pathology and Medical Research ICPMR, Westmead Hospital, New South Wales, Australia
    Semin Thromb Hemost 31:11-6. 2005
    ..This report briefly explores, from a scientist's perspective, some important issues that are sometimes overlooked...
  68. ncbi Factor V inhibitors: rare or not so uncommon? A multi-laboratory investigation
    Emmanuel J Favaloro
    Department of Haematology, Institute of Clinical Pathology and Medical Research, Westmead Hospital, Western Sydney Area Health Service, Westmead, NSW, Australia
    Blood Coagul Fibrinolysis 15:637-47. 2004
    ..29 cases per million Australians. Although considered a rare finding, there is a high likelihood that most haemostasis referral laboratories will see a case every five or so years...
  69. ncbi A 9-year retrospective assessment of laboratory testing for activated protein C resistance: evolution of a novel approach to thrombophilia investigations
    Emmanuel J Favaloro
    Department of Haematology, Institute of Clinical Pathology and Medical Research, Westmead Hospital, Western Sydney Area Health Service, NSW, Australia
    Pathology 34:348-55. 2002
    ..Also, to compare local results of FVL testing with a variety of different clot-based APCR assays to assess utility for detection of APCR both related and unrelated to FVL...
  70. ncbi Clinical application of the PFA-100
    Emmanuel J Favaloro
    Diagnostic Haemostasis Laboratory, Department of Hematology, Institute of Clinical Pathology and Medical Research, Westmead Hospital, Western Sydney Area Health Service, Westmead, NSW, 2145, Australia
    Curr Opin Hematol 9:407-15. 2002
    ..This review should be valuable to both hemostasis scientists and clinical specialists...
  71. ncbi Von Willebrand factor collagen-binding (activity) assay in the diagnosis of von Willebrand disease: a 15-year journey
    Emmanuel J Favaloro
    Diagnostic Haemostasis Laboratory, Department of Haematology, Institute of Clinical Pathology and Medical Research ICPMR, Westmead Hospital, Western Sydney Area Health Service, NSW, Australia
    Semin Thromb Hemost 28:191-202. 2002
    ..The vWF:CBA is also being investigated in various disease states, as is its usefulness as an effective marker of functional HMW vWF in both desmopressin (DDAVP) and factor-concentrate therapy in vWD...
  72. ncbi Phenotypic identification of platelet-type von Willebrand disease and its discrimination from type 2B von Willebrand disease: a question of 2B or not 2B? A story of nonidentical twins? Or two sides of a multidenominational or multifaceted primary-hemostas
    Emmanuel J Favaloro
    Department of Haematology, Institute of Clinical Pathology and Medical Research ICPMR, Westmead Hospital, Westmead, Australia
    Semin Thromb Hemost 34:113-27. 2008
    ..This article provides a review of PT-VWD-related literature and an overview of a phenotypic laboratory test process that should enable the effective identification of PT-VWD and its discrimination from 2B-VWD...
  73. ncbi Laboratory identification of von Willebrand disease: technical and scientific perspectives
    Emmanuel J Favaloro
    Department of Haematology, Institute of Clinical Pathology and Medical Research ICPMR, Westmead Hospital, Westmead, New South Wales, Australia
    Semin Thromb Hemost 32:456-71. 2006
    ..Selection of appropriate combination test panels and testing sequence is crucial for the proper diagnosis and classification of congenital vWD...
  74. ncbi Hemostatic dysfunction associated with endocrine disorders as a major risk factor and cause of human morbidity and mortality: a comprehensive meta-review
    Ashraf Mina
    Institute of Clinical Pathology and Medical Research ICPMR, Westmead Hospital, Westmead, Australia
    Semin Thromb Hemost 33:798-809. 2007
    ....
  75. ncbi Laboratory monitoring of therapy in von Willebrand disease: efficacy of the PFA-100 and von Willebrand factor:collagen-binding activity as coupled strategies
    Emmanuel J Favaloro
    Diagnostic Haemostasis Laboratory, Department of Haematology, Institute of Clinical Pathology and Medical Research, Westmead Hospital, Westmead, New South Wales, Australia
    Semin Thromb Hemost 32:566-76. 2006
    ..This review should be of value to both hemostasis scientists and clinical specialists...
  76. ncbi The utility of the PFA-100 in the identification of von Willebrand disease: a concise review
    Emmanuel J Favaloro
    Department of Haematology, Institute of Clinical Pathology and Medical Research ICPMR, Westmead Hospital, Westmead, New South Wales, Australia
    Semin Thromb Hemost 32:537-45. 2006
    ....
  77. ncbi Mis-identification of factor inhibitors by diagnostic haemostasis laboratories: recognition of pitfalls and elucidation of strategies. A follow up to a large multicentre evaluation
    Emmanuel J Favaloro
    Department of Haematology and Royal College of Pathologists of Australasia Quality Assurance Program, Institute of Clinical Pathology and Medical Research, Westmead Hospital, New South Wales 2145, Australia
    Pathology 39:504-11. 2007
    ....
  78. ncbi Utility of the PFA-100 as a screening test of platelet function: an audit of haemostasis laboratories in Australia and New Zealand
    Emmanuel J Favaloro
    Department of Haematology and Royal College of Pathologists of Australasia Quality Assurance Program, Institute of Clinical Pathology and Medical Research, Westmead Hospital, New South Wales, Australia
    Blood Coagul Fibrinolysis 18:441-8. 2007
    ..e. classical aggregation). Most abnormal findings, however, were attributed to antiplatelet medication such as aspirin...
  79. ncbi 2B or not 2B? Disparate discrimination of functional VWF discordance using different assay panels or methodologies may lead to success or failure in the early identification of type 2B VWD
    Emmanuel J Favaloro
    Department of Haematology, Institute of Clinical Pathology and Medical Research ICPMR, SWAHS, Westmead, New South Wales, 2145, Australia
    Thromb Haemost 98:346-58. 2007
    ..On the basis of these findings, we provide a series of recommendations to enable the appropriate laboratory identification of VWD, in particular type 2B VWD...
  80. ncbi Emerging technologies and quality assurance in hemostasis: a review of findings from the Royal College of Pathologists of Australasia Quality Assurance Program
    Emmanuel J Favaloro
    Department of Haematology, RCPA Quality Assurance Program, Institute of Clinical Pathology and Medical Research, Westmead Hospital, New South Wales, Australia
    Semin Thromb Hemost 33:235-42. 2007
    ....
  81. ncbi Comparison of the pharmacokinetics of two von Willebrand factor concentrates [Biostate and AHF (High Purity)] in people with von Willebrand disorder. A randomised cross-over, multi-centre study
    Emmanuel J Favaloro
    Haematology, Institute of Clinical Pathology and Medical Research ICPMR, Westmead Hospital, SWAHS, Westmead, NSW, 2145, Australia
    Thromb Haemost 97:922-30. 2007
    ..PFA-100 CTs did not adequately reflect changes in these VWF parameters. Based on these results, one would expect Biostate to be at least as effective, if not superior to AHF (High Purity) for the treatment of VWD...
  82. ncbi Reducing errors in identification of von Willebrand disease: the experience of the royal college of pathologists of australasia quality assurance program
    Emmanuel J Favaloro
    Department of Haematology, Institute of Clinical Pathology and Medical Research ICPMR, Westmead Hospital, Westmead, New South Wales, Australia
    Semin Thromb Hemost 32:505-13. 2006
    ..We conclude that although laboratories are generally proficient in tests for vWD, diagnostic errors do occur and error rates are substantially reduced when test panels are more comprehensive and include the vWF:CB...
  83. ncbi Direct-to-consumer testing: more risks than opportunities
    G Lippi
    U O Diagnostica Ematochimica, Azienda Ospedaliero Universitaria di Parma, Parma, Italy Department of Haematology, Institute of Clinical Pathology and Medical Research ICPMR, Westmead Hospital, Westmead, NSW, Australia Dipartimento di Medicina di Laboratorio, Azienda Ospedaliera di Padova, Padova, Italy
    Int J Clin Pract 65:1221-9. 2011
    ..benefit analyses are needed to definitely establish whether DTC testing might be effective for decreasing the burden of diseases, delay their onset or modify their progression and therefore the clinical outcome...
  84. ncbi Laboratory assessment as a critical component of the appropriate diagnosis and sub-classification of von Willebrand's disease
    E J Favaloro
    Department of Haematology, Institute of Clinical Pathology and Medical Research, Westmead Hospital, WSAHS, Australia
    Blood Rev 13:185-204. 1999
    ..This review should be of value to both haemostasis scientists and clinical specialists involved in VWD diagnosis...
  85. ncbi Assessing the usefulness of anticardiolipin antibody assays: a cautious approach is suggested by high variation and limited consensus in multilaboratory testing
    Emmanuel J Favaloro
    Department of Haematology, Institute of Clinical Pathology and Medical Research, Westmead Hospital, Western Sydney Area Health Service, New South Wales, Australia
    Am J Clin Pathol 118:548-57. 2002
    ..Laboratory tests should be repeated at least once before making a clinical diagnosis of any anti-phospholipid syndrome-like disorder...
  86. ncbi Clinical audit of antiphospholipid antibody testing in tertiary practice: towards improved relevance in thrombophilia investigations
    E J Favaloro
    Department of Haematology, ICPMR, Westmead Hospital, SWAHS, Sydney, New South Wales, Australia
    Intern Med J 42:427-34. 2012
    ..We also observed a moderate rate (46%) of coincidence of aCL and LA, in agreement with guidelines indicating that multiple tests are required to identify APS...
  87. ncbi Human endothelial cells maintain anti-aggregatory activity for platelets during apoptosis
    W Xu
    Department of Oral Pathology and Oral Medicine, University of Sydney, Westmead Hospital Dental Clinical School, Westmead Hospital, NSW, Australia
    Thromb Haemost 85:915-23. 2001
    ..These data support the idea that EC maintain active antithrombotic activity during apoptosis, consistent with maintained urokinase levels and canalicular fragmentation reported elsewhere...
  88. ncbi Sulfatide-binding assay for von Willebrand factor. Detection of von Willebrand's disease without discrimination of vWD subtypes
    E J Favaloro
    Department of Haematology, Institute of Clinical Pathology and Medical Research ICPMR, Westmead Hospital, Western Sydney Area Health Service, Westmead, Australia
    Thromb Res 98:213-9. 2000
    ....
  89. ncbi Assessment of current diagnostic practice and efficacy in testing for von Willebrand's disorder: results from the second Australasian multi-laboratory survey
    E J Favaloro
    Department of Haematology, Institute of Clinical Pathology and Medical Research, Westmead Hospital, NSW, Australia
    Blood Coagul Fibrinolysis 11:729-37. 2000
    ....
  90. ncbi Possibility of potential VWD misdiagnosis or misclassification using LIA technology and due to presence of rheumatoid factor
    E J Favaloro
    Department of Haematology, ICPMR, Westmead Hospital, Australia
    Am J Hematol 66:53-6. 2001
    ....
  91. ncbi Circulating inflammatory markers and hemostatic factors in age-related maculopathy: a population-based case-control study
    Kathy H C Wu
    the Center for Vision Research, Department of Ophthalmology, University of Sydney, Westmead Hospital, Westmead, NSW, Australia
    Invest Ophthalmol Vis Sci 48:1983-8. 2007
    ..To examine the relationship between circulating inflammatory markers, hemostatic factors, and age-related maculopathy (ARM)...
  92. ncbi Antiphospholipid antibodies and the antiphospholipid syndrome II: limitations, standardization, and clinical utility of laboratory testing
    Emmanuel J Favaloro
    Department of Haematology, Institute of Clinical Pathology and Medical Research (ICPMR, Westmead Hospital, SWAHS, Westmead, NSW, Australia
    Semin Thromb Hemost 34:309-12. 2008
  93. ncbi Hot topics II: an editorial collection of current issues and controversies in thrombosis and hemostasis
    Emmanuel J Favaloro
    Department of Haematology, Institute of Clinical Pathology and Medical Research (ICPMR, Westmead Hospital, SWAHS, Westmead, Australia
    Semin Thromb Hemost 34:3-6. 2008
  94. ncbi CD13 (GP150; aminopeptidase-N): predominant functional activity in blood is localized to plasma and is not cell-surface associated
    E J Favaloro
    Department of Haematology, Westmead Hospital, New South Wales, Australia
    Exp Hematol 21:1695-701. 1993
    ..These findings have significant implications for our understanding of the many functions of this molecule in blood...
  95. ncbi Identification of von Willebrand disease type 2N (Normandy) in Australia: a cross-laboratory investigation using different methods
    Susan E Rodgers
    Haemostasis Laboratory, Haematology Division, Institute of Medical and Veterinary Science, University of South Australia, Adelaide, Australia
    Am J Clin Pathol 118:269-76. 2002
    ..The 2-stage factor VIII assay was more useful as a screening test than the 1-stage assay, and both vWF-factor VIII binding assays were equally effective...
  96. ncbi Investigating people with mucocutaneous bleeding suggestive of primary hemostatic defects: a low likelihood of a definitive diagnosis?
    Emmanuel J Favaloro
    Haematologica 92:292-6. 2007
  97. ncbi The paradoxical relationship between serum uric acid and cardiovascular disease
    Giuseppe Lippi
    Sezione di Chimica Clinica, Dipartimento di Scienze Biomediche e Morfologiche, Universita di Verona, Italy
    Clin Chim Acta 392:1-7. 2008
    ..The aim of this article is to review uric acid metabolism and physiology, highlighting its association with cardiovascular disease...
  98. ncbi A consensus approach to the formulation of guidelines for laboratory testing and reporting of antiphospholipid antibody assays
    Richard C W Wong
    Division of Immunology, Pathology Queensland, Royal Brisbane and Womens Hospital, Herston, Queensland, Australia
    Semin Thromb Hemost 34:361-72. 2008
    ....
  99. ncbi Cold storage of citrated whole blood induces drastic time-dependent losses in factor VIII and von Willebrand factor: potential for misdiagnosis of haemophilia and von Willebrand disease
    Martina Bohm
    Department of Internal Medicine, Johann Wolfgang Goethe University Hospital, Frankfurt am Main, Germany
    Blood Coagul Fibrinolysis 17:39-45. 2006
    ..These results suggest a serious potential for misdiagnosis of haemophilia or VWD due to inappropriate pre-analytical handling of blood...
  100. ncbi von Willebrand disease, type 2B: A diagnosis more elusive than previously thought
    Emmanuel J Favaloro
    Thromb Haemost 99:630-1; author reply 632-3. 2008
  101. ncbi Differential identification of a rare form of platelet-type (pseudo-) von Willebrand disease (VWD) from Type 2B VWD using a simplified ristocetin-induced-platelet-agglutination mixing assay and confirmed by genetic analysis
    Emmanuel J Favaloro
    Br J Haematol 139:623-6. 2007